course_id=37cb2012-8aba-4dbc-99db-b1448d144094|::|firstname=Kheng Yee|::|lastname=Wah|::|[email protected]|::|country=Malaysia|::|state=Kuala Lumpur|::|ha=wisma kdm c-2-10, plaza damas, NO 60 jalan SRI hartamas 1 50480 - WILAYAH PERSEKUTUAN KUALA LUMPUR|::|speciality=Non-Clinical|::|experience=|::|city=|::|timestamp=
Novel Approach to Treatment Resistant Depression - Part 1
Modules 1 is part 1 of 4-part course series on "Novel Approach to Treatment Resistant Depression".
To pass this course and earn 1 CPD credit, doctors need to view a video and successfully complete a set of questions.
This course is limited only to licensed psychiatrist.
Duration of this course: approximately 30 minutes.
Duration of total course series: 2 hours - 2 hours 30 minutes.
Module 1: Disease Burden of Depression and Treatment Resistant DepressionLearning objectives:
Describe the prevalence, natural history, and diagnosis of major depressive disorder and treatment-resistant depression
Describe the challenges in achieving and maintaining remission in patients with treatment-resistant depression
Describe the additional medical, disability, and mortality burden in patients with treatment-resistant depression
Module 2: Mechanism of Disease and the Innovative Role of Esketamine in Addressing DepressionLearning objectives:
Describe how the impairment of synaptic plasticity can lead to reduced synaptic connections in the brains of patients with major depressive disorder
Describe the role of glutamate in maintaining synaptic connections and how alterations in glutamate signaling contribute to the development of major depressive disorder
Describe the novel mechanism of action for esketamine and how this approach may be used to restore synaptic connections in the brains of patients with major depressive disorder
Module 3: Innovations in the Management of TRDLearning objectives:
Describe the development of intranasal esketamine for treatment-resistant depression and major depression with suicidal ideation
Describe the clinical evidence supporting the efficacy of intranasal esketamine for treatment-resistant depression
Describe the clinical evidence supporting the safety of intranasal esketamine for treatment-resistant depression
Module 4: Important Considerations in the Administration of Esketamine for TRDLearning objectives:
Describe the novel design of esketamine nasal spray and the recommended instructions for administration in the treatment of depression
Describe the most common adverse events due to esketamine use and the best approach to post-administration patient monitoring
Describe the built-in precautions which promote the safe use of esketamine and mitigate the risk of abuse
Module 5: Clinical Case StudiesLearning objectives:
Apply clinical evidence regarding the efficacy and safety of esketamine to a spectrum of clinical scenarios involving patients with treatment-resistant depression
This CPD activity is done in collaboration with Johnson & Johnson Sdn Bhd.
Upon viewing the video and successfully completing the quiz in this module, you will be given 1 CPD point, that will be credited instantly in your MMA CPD account.To pass this module, get at least 9 out 11 questions correct.
Update your course progress statusThis course is hosted by Johnson & Johnson Institute (J&J). Once you have completed the course, please click the button below to retrieve your up-to-date course progress status from J&J.Note: It will take several seconds to retrieve your learning record.
... retrieving data from J&J Institute
Certificate of completionTo attain the certificate of completion on J&J platform, after successfully completing the course modules, doctors must complete the course evaluation.